Drug intelligence / Profile preview

celecoxib + meloxicam + imrecoxib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three nonsteroidal anti-inflammatory drugs (NSAIDs): celecoxib (Celebrex), meloxicam (Mobic), and imrecoxib. Celecoxib and meloxicam are both COX-2 selective NSAIDs used to treat pain and inflammation associated with conditions like osteoarthritis and rheumatoid arthritis. Taking multiple NSAIDs together is generally not recommended due to increased risk of gastrointestinal side effects such as bleeding and ulcers without improving pain relief. A major drug interaction exists between celecoxib and meloxicam.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on celecoxib + meloxicam + imrecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib + meloxicam + imrecoxib.

Explore the full profile